



UNITED STATES PATENT AND TRADEMARK OFFICE

APR - 2 2009

Commissioner for Patents  
United States Patent and Trademark Office  
Mailstop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Gregory D. Ferraro  
Novartis  
Corporate Intellectual Property  
One Health Plaza Building 104  
East Hanover, NJ 07936-1080

In Re: Patent Term Extension  
Application for  
U.S. Patent No. 5,559,111

**NOTICE OF FINAL DETERMINATION**

A determination has been made that U.S. Patent No. 5,559,111, which claims the human drug product TEKTURNA® (aliskiren hemifumarate), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 1,204 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 1,204 days.

The period of extension has been calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of May 2, 2008 (73 Fed. Reg. 24295). Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} \text{ (Testing Phase)} + \text{Approval Phase} \\ &= \frac{1}{2} (1,637 \text{ days}) + 386 \text{ days} \\ &= 1,204 \text{ days (3.3 years)}\end{aligned}$$

Since the regulatory review period began August 22, 2001, after the patent issued (September 24, 1996), the entire regulatory review period has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

Neither the limitations of 35 U.S.C. § 156(g)(6) nor 35 U.S.C. § 156(c)(3) operate to reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.: 5,559,111

Granted: September 24, 1996

Original Expiration Date<sup>1</sup>: April 4, 2015  
Applicant: Richard Göschke et al.  
Owner of Record: Novartis Corporation  
Title: δ-Amino-γ-hydroxy-ω-aryl-alkanoic acid amides  
Product Trade Name: TEKTURNA® (aliskiren hemifumarate)  
Term Extended: 1,204 days  
Expiration Date of Extension: July 21, 2018

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450.  
By FAX: (571) 273-7755

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755.



Mary C. Till  
Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

RE: TEKTURNA® (Aliskiren  
hemifumarate)  
Docket No.: FDA-2007-E-0282

Attention: Beverly Friedman

---

<sup>1</sup>Subject to the provisions of 35 U.S.C. § 41(b).